New biomarker analyses from the phase 3 KEYNOTE-522 trial presented at the San Antonio Breast Cancer Symposium 2024 provide insights into factors influencing response to pembrolizumab plus chemotherapy in early-stage triple-negative breast cancer (TNBC). The study examined biomarkers like TMB and T-cell–inflamed GEP in relation to pCR and EFS. T-cell inflammation and TMB were associated with pCR and EFS benefits. The analysis also looked at molecular subtypes, highlighting the LAR subtype, and HRD status. While the combination of pembrolizumab plus chemotherapy showed efficacy across biomarker subgroups, researchers emphasize the need for further biomarker-driven treatment selection and future research to optimize immunotherapy strategies for TNBC patients.
Source link
Exploratory Analysis Identifies Biomarkers of Response in TNBC
